Page last updated: 2024-08-24

irinotecan and Chromosome Deletion

irinotecan has been researched along with Chromosome Deletion in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	2 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bacon, O; Barat, A; Betge, J; Biesma, HD; Byrne, AT; Cordes, M; Das, S; Ebert, MPA; Eijk, PP; Fender, B; Gaiser, T; Gallagher, WM; Hennessey, BT; Kay, EW; Klinger, R; Koopman, M; Lambrechts, D; Loupakis, F; McNamara, DA; Meijer, GA; Murphy, V; Neerincx, M; O'Connor, DP; Prehn, JHM; Punt, CJA; Smeets, D; van Dijk, E; van Grieken, NCT; Verheul, HMW; Ylstra, B	1
Agama, K; Brünner, N; Doroshow, JH; Jensen, NF; Knudsen, BR; Pfister, TD; Pommier, Y; Roy, A; Rømer, MU; Smith, DH; Stenvang, J; Zhang, HL	1
Italiano, A; Sablin, MP; Spano, JP	1
Chamberlain, MC; Glantz, MJ	1

Reviews

1 review(s) available for irinotecan and Chromosome Deletion

Article	Year
[Colorectal cancers: prognostic and predictive factors of response to treatment]. Bulletin du cancer, 2009, Volume: 96, Issue:4 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Chromosome Deletion; Chromosomes, Human, Pair 18; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Panitumumab; Prognosis	2009

Article

Year

[Colorectal cancers: prognostic and predictive factors of response to treatment].

Bulletin du cancer, 2009, Volume: 96, Issue:4

Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Chromosome Deletion; Chromosomes, Human, Pair 18; Colorectal Neoplasms; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Neoplasm Staging; Panitumumab; Prognosis

2009

Trials

2 trial(s) available for irinotecan and Chromosome Deletion

Article	Year
Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 07-10, Volume: 36, Issue:20 Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chromosome Deletion; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 18; Chromosomes, Human, Pair 5; Clinical Trials, Phase III as Topic; Cohort Studies; Colorectal Neoplasms; Comparative Genomic Hybridization; Female; Genetic Testing; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Progression-Free Survival; Reproducibility of Results	2018
CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma. Journal of neuro-oncology, 2008, Volume: 89, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Chromosome Deletion; Chromosomes, Human, Pair 1; Dacarbazine; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Survival Analysis; Temozolomide	2008

Article

Year

Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018, 07-10, Volume: 36, Issue:20

Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Chromosome Deletion; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 18; Chromosomes, Human, Pair 5; Clinical Trials, Phase III as Topic; Cohort Studies; Colorectal Neoplasms; Comparative Genomic Hybridization; Female; Genetic Testing; Humans; Irinotecan; Male; Middle Aged; Neoplasm Metastasis; Oxaliplatin; Progression-Free Survival; Reproducibility of Results

2018

CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma.

Journal of neuro-oncology, 2008, Volume: 89, Issue:2

Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Brain Neoplasms; Camptothecin; Chromosome Deletion; Chromosomes, Human, Pair 1; Dacarbazine; Female; Humans; Irinotecan; Male; Middle Aged; Neoplasm Recurrence, Local; Oligodendroglioma; Survival Analysis; Temozolomide

2008

Other Studies

1 other study(ies) available for irinotecan and Chromosome Deletion

Article	Year
Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations. Journal of experimental & clinical cancer research : CR, 2016, Mar-31, Volume: 35 Topics: Benzodioxoles; Binding Sites; Camptothecin; Cell Line, Tumor; Chromosome Deletion; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Gene Dosage; Guanidines; HCT116 Cells; HT29 Cells; Humans; Hydrazones; Irinotecan; Isoquinolines; Mutation	2016

Article

Year

Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.

Journal of experimental & clinical cancer research : CR, 2016, Mar-31, Volume: 35

Topics: Benzodioxoles; Binding Sites; Camptothecin; Cell Line, Tumor; Chromosome Deletion; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Epirubicin; Etoposide; Gene Dosage; Guanidines; HCT116 Cells; HT29 Cells; Humans; Hydrazones; Irinotecan; Isoquinolines; Mutation

2016